Prophylaxis of respiratory syncytial virus infection: current status and prospects for vaccine development

INTRODUCTION. Respiratory syncytial virus (RSV) is one of the most widespread pathogens that typically cause acute upper and lower respiratory tract infections in children and adults. Monoclonal antibody products have long been used for passive immunoprophylaxis in premature infants with bronchopulmonary dysplasia. However, vaccines have recently been licensed for the prophylactic immunisation of older adults with various risk factors for severe RSV infection (primarily, chronic cardiovascular and respiratory diseases and diabetes mellitus).

AIM. This study aimed to review the current status of the development of vaccines for active immunisation against RSV infection, including the epidemiological rationale for their development, clinical trial results for licensed vaccines, recommendations for vaccination, and promising pipeline vaccines for RSV prevention.

DISCUSSION. Initially hindered by the unique immunopathogenesis of RSV infection and the genetic hypervariability of RSV for a long time, attempts to develop an RSV vaccine succeeded when international researchers managed to identify a conservative neutralising antibody target capable of inducing specific immunity against RSV. This target, the RSV capsid protein stabilised in its prefusion (pre-F) conformation, can mediate viral entry into the cell following a conformational change. Several subunit vaccines based on recombinant pre-F proteins have successfully passed clinical trials and have been approved for the immunisation of older adults. In addition, one of these vaccines has been recommended for use during pregnancy to prevent RSV infection in newborns and infants. Currently, programmes are being implemented to develop novel RSV vaccines based on messenger RNA (mRNA) and non-replicating attenuated influenza vectors. This article examines and summarises the efficacy and safety parameters of two RSV vaccines approved in multiple countries around the world. Both vaccines have satisfactory safety profiles and comparable prophylactic efficacy parameters.

CONCLUSIONS. Prelicensure clinical trials of novel RSV vaccines, including those being developed in the Russian Federation, should include prophylactic efficacy assessments in target patient populations. For vaccines approved by leading international regulators, clinical trials required for approval in the Russian Federation will be limited to bridging studies confirming the immunogenicity and safety of the vaccines.

1. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and highrisk adults. N Engl J Med. 2005;352(17):1749–59. https://doi.org/10.1056/nejmoa043951

2. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102(3):531–7. PMID: 9738173

3. Reicherz F, Abu-Raya B, Akinseye O, Rassekh SR, Wiens MO, Lavoie PM. Efficacy of palivizumab immunoprophylaxis for reducing severe RSV outcomes in children with immunodeficiencies: a systematic review. J Pediatric Infect Dis Soc. 2024;13(2):136–43. https://doi.org/10.1093/jpids/piae004

4. Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, et al. Respiratory syncytial virus prefusion F protein vaccine in older adults. N Engl J Med. 2023;388(7):595–608. https://doi.org/10.1056/nejmoa2209604

5. Walsh EE, Pérez Marc G, Zareba AM, Falsey AR, Jiang Q, Patton M, et al. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N Engl J Med. 2023;388(16):1465–77. https://doi.org/10.1056/nejmoa2213836

6. Melgar M, Britton A, Roper LE, Talbot HK, Long SS, Kot ton CN, Havers FP. Use of respiratory syncytial virus vaccines in older adults: recommendations of the advisory committee on immunization practices — United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(29):793–801. https://doi.org/10.15585/mmwr.mm7229a4

7. Acosta P, Caballero MT, Polack FP. Brief history and characterization of enhanced respiratory syncytial virus disease. Clin Vaccine Immunol. 2016;23(3):189–95. https://doi.org/10.1128/cvi.00609-15

8. Altamirano-Lagos MJ, Díaz FE, Mansilla MA, Rivera-Pérez D, Soto D, McGill JL, et al. Current animal models for understanding the pathology caused by the respiratory syncytial virus. Front Microbiol. 2019;10:873. https://doi.org/10.3389/fmicb.2019.00873

9. Walsh EE, Hall CB. Respiratory Syncytial Virus (RSV). Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 2015:1948–1960.e3. https://doi.org/10.1016/B978-1-4557-4801-3.00160-0

10. van den Hoogen BG, de Jong JC, Groen J, Kuiken T, de Groot R, Fouchier RA, Osterhaus AD. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med. 2001;7(6):719–24. https://doi.org/10.1038/89098

11. Collins PL, Fearns R, Graham BS. Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease. Curr Top Microbiol Immunol. 2013;372:3–38. https://doi.org/10.1007/978-3-642-38919-1_1

12. Tawar RG, Duquerroy S, Vonrhein C, Varela PF, DamierPiolle L, Castagne N, et al. Crystal structure of a nucleocapsid-like nucleoprotein-RNA complex of respiratory syncytial virus. Science. 2009;326(5957):1279–83. https://doi.org/10.1126/science.1177634

13. Yu JM, Fu YH, Peng XL, Zheng YP, He JS. Genetic diversity and molecular evolution of human respiratory syncytial virus A and B. Sci Rep. 2021;11(1):12941. https://doi.org/10.1038/s41598-021-92435-1

14. Tan L, Lemey P, Houspie L, Viveen MC, Jansen NJ, van Loon AM, et al. Genetic variability among complete human respiratory syncytial virus subgroup A genomes: bridging molecular evolutionary dynamics and epidemiology. PLoS One. 2012;7(12):e51439. https://doi.org/10.1371/journal.pone.0051439

15. Vos LM, Oosterheert JJ, Kuil SD, Viveen M, Bont LJ, Hoepelman AIM, Coenjaerts FEJ. High epidemic burden of RSV disease coinciding with genetic alterations causing amino acid substitutions in the RSV G-protein during the 2016/2017 season in The Netherlands. J Clin Virol. 2019;112:20–26. https://doi.org/10.1016/j.jcv.2019.01.007

16. König P, Giesow K, Schuldt K, Buchholz UJ, Keil GM. A novel protein expression strategy using recombinant bovine respiratory syncytial virus (BRSV): modifications of the peptide sequence between the two furin cleavage sites of the BRSV fusion protein yield secreted proteins, but affect processing and function of the BRSV fusion protein. J Gen Virol. 2004;85(Pt 7):1815–24. https://doi.org/10.1099/vir.0.80010-0

17. Yusuf S, Piedimonte G, Auais A, Demmler G, Krishnan S, Van Caeseele P, et al. The relationship of meteorological conditions to the epidemic activity of respiratory syncytial virus. Epidemiol Infect. 2007;135(7):1077–90. https://doi.org/10.1017/S095026880600776X

18. Hansen CL, Chaves SS, Demont C, Viboud C. Mortality associated with influenza and respiratory syncytial virus in the US, 1999–2018. JAMA Netw Open. 2022;5(2):e220527. https://doi.org/10.1001/jamanetworkopen.2022.0527

19. Johnstone J, Majumdar SR, Fox JD, Marrie TJ. Viral infection in adults hospitalized with community-acquired pneumonia: prevalence, pathogens, and presentation. Chest. 2008;134(6):1141–8. https://doi.org/10.1378/chest.08-0888

20. L’vov DK, Burtseva EI, Kolobukhina LV, Fedyakina IT, Bovin NV, et al. Peculiarities of the influenza and ARVI viruses during epidemic season 2019–2020 in some regions of Russia. Problems of Virology. 2020;65(6):335–49 (In Russ.). https://doi.org/10.36233/0507-4088-2020-65-6-4

21. Kim HW, Ganchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parroth RH. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;89(4):422–34. https://doi.org/10.1093/oxfordjournals.aje.a120955

22. Johnson PR, Collins PL. The fusion glycoproteins of human respiratory syncytial virus of subgroups A and B: sequence conservation provides a structural basis for antigenic relatedness. J Gen Virol. 1988;69(Pt 10):2623–8. https://doi.org/10.1099/0022-1317-69-10-2623

23. Calder LJ, González-Reyes L, García-Barreno B, Wharton SA, Skehel JJ, Wiley DC, Melero JA. Electron microscopy of the human respiratory syncytial virus fusion protein and complexes that it forms with monoclonal antibodies. Virology. 2000;271(1):122–31. https://doi.org/10.1006/viro.2000.0279

24. Smith BJ, Lawrence MC, Colman PM. Modelling the structure of the fusion protein from human respiratory syncytial virus. Protein Eng. 2002;15(5):365–71. https://doi.org/10.1093/protein/15.5.365

25. McLellan JS, Chen M, Leung S, Graepel KW, Du X, Yang Y, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science. 2013;340(6136):1113–7. https://doi.org/10.1126/science.1234914

26. McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GB, Yang Y, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science. 2013;342(6158):592–8. https://doi.org/10.1126/science.1243283

27. Crank MC, Ruckwardt TJ, Chen M, Morabito KM, Phung E, Costner PJ, et al. A proof of concept for structure-based vaccine design targeting RSV in humans. Science. 2019;365(6452):505–9. https://doi.org/10.1126/science.aav9033

28. Stephens LM, Varga SM. Considerations for a respiratory syncytial virus vaccine targeting an elderly population. Vaccines (Basel). 2021;9(6):624. https://doi.org/10.3390/vaccines9060624

29. Walsh EE, Falsey AR, Scott DA, Gurtman A, Zareba AM, Jansen KU, et al. A randomized phase 1/2 study of a respiratory syncytial virus prefusion F vaccine. J Infect Dis. 2022;225(8):1357–66. https://doi.org/10.1093/infdis/jiab612

30. Leroux-Roels I, Davis MG, Steenackers K, Essink B, Vandermeulen C, Fogarty C, et al. Safety and immunogenicity of a respiratory syncytial virus prefusion F (RSVPreF3) candidate vaccine in older adults: phase 1/2 randomized clinical trial. J Infect Dis. 2023;227(6):761–72. https://doi.org/10.1093/infdis/jiac327

31. Ferguson M, Murray A, Pliamm L, Rombo L, Sanmartin Berglund J, David MP, et al. Lot-to-lot immunogenicity consistency of the respiratory syncytial virus prefusion F protein vaccine in older adults. Vaccine X. 2024;18:100494. https://doi.org/10.1016/j.jvacx.2024.100494

32. Schmoele-Thoma B, Zareba AM, Jiang Q, Maddur MS, Danaf R, Mann A, et al. Vaccine efficacy in adults in a respiratory syncytial virus challenge study. N Engl J Med. 2022;386(25):2377–86. https://doi.org/10.1056/nejmoa2116154

33. Athan E, Baber J, Quan K, Scott RJ, Jaques A, Jiang Q, et al. Safety and immunogenicity of bivalent RSVpreF vaccine coadministered with seasonal inactivated influenza vaccine in older adults. Clin Infect Dis. 2024;78(5):1360–8. https://doi.org/10.1093/cid/ciad707

34. Kampmann B, Madhi SA, Munjal I, Simões EAF, Pahud BA, Llapur C, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023;388(16):1451–64. https://doi.org/10.1056/nejmoa2216480

35. Baker J, Aliabadi N, Munjal I, Jiang Q, Feng Y, Brock LG, et al. Equivalent immunogenicity across three RSVpreF vaccine lots in healthy adults 18–49 years of age: Results of a randomized phase 3 study. Vaccine. 2024;42(13):3172–9. https://doi.org/10.1016/j.vaccine.2024.03.070

36. Vasin AV, Egorov AYu, Sergeeva MV, Stukova MA. Recombinant vector constructs based on attenuated influenza virus for the development of vaccines against respira tory infections. In: III Joint Scientific Forum of Physiologists, Biochemists and Molecular Biologists. VII Congress of Russian Biochemists. X Russian Symposium “Proteins and Peptides”. VII Congress of CIS Physiologists. Vol. 2. Moscow: Pero; 2021. P. 229–30 (In Russ.). EDN: SXYWDM

37. Wilson E, Goswami J, Baqui AH, Doreski PA, PerezMarc G, Zaman K, et al. Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults. N Engl J Med. 2023;389(24):2233–44. https://doi.org/10.1056/nejmoa2307079

38. Karron RA, Luongo C, Mateo JS, Wanionek K, Collins PL, Buchholz UJ. Safety and immunogenicity of the respiratory syncytial virus vaccine RSV/ΔNS2/Δ1313/ I1314L in RSV-seronegative children. J Infect Dis. 2020;222(1):82–91. https://doi.org/10.1093/infdis/jiz408